GET DAILY SIGNALSGilead Sciences (GILD) Analysts Eye +11% Upside Toward $190 Target
Key Takeaways
- The central target of $190 is the average of 11 verified analyst price targets that sit above the latest price, not an official consensus figure.
- Shares of Gilead Sciences (GILD) closed near $170.68, meaning the target implies roughly an 11% upside.
- Across 14 recent targets reviewed, the overall mean is about $178 and the range is unusually wide, from $131 to $200.
- Supporting factors include a Q3 beat-and-raise, accelerating HIV growth, and strong PrEP (pre-exposure prophylaxis) momentum for Yeztugo.
- Key risks include pipeline and patent-cliff concerns, valuation pressure after a sharp run-up, and a cautious low-end view from firms such as RBC Capital.
- You can review more detail on GILD's Major News, Today's Price Move, Forecast, and Earnings on Tickeron's dedicated pages.
- For automated stock and ETF ideas, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Gilead Sciences, Inc. is a biopharmaceutical company best known for its HIV and antiviral franchises. I reviewed fourteen current analyst price targets. They span a very wide range, from $131 (RBC Capital, Sector Perform) to $200 (Scotiabank and Needham). Because the overall mean of all 14 targets sits near $178—only about 4% above the latest price—it fails a meaningful minimum-distance test. The $190 central target is therefore calculated as the average of the 11 verified targets that are above the current price, and it is presented as such rather than as an official consensus.
Recent post-earnings revisions were predominantly upward. JPMorgan and Wells Fargo each moved to $190, Scotiabank and Needham to $200, UBS to $195, Citi to $188, BMO Capital to $184, Morgan Stanley to $183, Truist to $181, and TD Cowen and Cantor Fitzgerald to $175. The most cautious views include RBC Capital at $131, Goldman Sachs at $142, and Bernstein at $160. The wide spread reflects genuine disagreement about how durable Gilead's HIV growth and oncology pipeline will prove. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The latest verified closing price is approximately $170.68, a record high reached after shares gained over 3% on the Q3 report. Reaching $190 requires about 11% further upside—a substantial but not extreme move for a large-cap pharmaceutical name following a strong quarter.
The path would likely depend on sustained execution. Gilead reported non-GAAP EPS of $2.55, well above the roughly $2.17 consensus, on revenue of about $8.3 billion versus expectations near $7.79 billion. Core business revenue rose roughly 16% year over year, the strongest growth in more than a decade, and management raised full-year guidance. Continued HIV franchise momentum—now expected to grow about 12%—and successful commercialization of the weekly oral PrEP option would be central to any move toward $190.
What Could Support a Move Toward the Target
- HIV beat-and-raise: HIV growth was lifted to roughly 12% from a prior 9%–10% view, with Yeztugo (lenacapavir) outperforming consensus.
- PrEP expansion: A regulatory decision on an oral, once-weekly PrEP option is expected around February 2027, which analysts see as a potential growth accelerant.
- Guidance momentum: Management raised full-year revenue guidance after the strong Q3, and multiple analysts raised targets on execution.
- Broad revenue base: Strength spanned HIV, oncology, and liver disease, reducing reliance on any single product.
What Could Prevent the Target From Being Reached
- Valuation after the run-up: The stock has climbed sharply and trades near record levels, which raises the bar for further gains.
- Pipeline and patent concerns: Investors continue to scrutinize long-term growth beyond the HIV franchise, including oncology and inflammation programs.
- Divergent analyst views: The $131–$200 spread shows some firms see limited upside, reflecting uncertainty about growth sustainability.
- Sector sensitivity: Regulatory decisions, competitive PrEP entrants, and broader biotech risk appetite could weigh on sentiment.
Technical Levels and Market Structure
Gilead has been in a strong uptrend, gaining roughly 37% year to date and setting successive record highs. The prior 52-week high near $165.70 was cleared decisively, and an intraday peak near $175.65 on the earnings day marked the highest level in the company's history before shares gave back some gains. The $165–$166 area now represents a potential support zone, while $175–$176 marks near-term resistance from that intraday high. A sustained push above $175 would open the door toward the $190 level, whereas a retreat below the prior high could signal that the post-earnings move is consolidating.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of about 12 months, though individual firms may vary. Investors should watch upcoming quarterly results and guidance, the February 2027 regulatory decision on the weekly oral PrEP option, HIV and Yeztugo sales trends, and any further analyst revisions. Developments in the oncology and inflammation pipeline, along with broader interest-rate and healthcare-sector sentiment, also matter for the valuation multiple the market assigns to Gilead.
Exploring AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. This can help traders scan for opportunities, track existing positions, and identify changing trends more efficiently than manual review. I find these signals useful when monitoring names like GILD as part of my broader research process, especially after earnings moves like the one we just saw.
Final Assessment
The $190 central target reflects the average of analyst targets above the current price, a figure that requires roughly 11% upside from the latest close near $170.68. The bull case rests on a genuine Q3 beat-and-raise, accelerating HIV growth, and a promising PrEP catalyst in early 2027. The bear case centers on valuation after a steep rally, pipeline longevity questions, and a wide $131–$200 target range that signals meaningful disagreement. Whether GILD reaches $190 will depend on sustained execution and the market's willingness to pay a higher multiple; the outcome is far from guaranteed.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for GILD turns positive, indicating new upward trend
GILD saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 57 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GILD just turned positive on October 14, 2026. Looking at past instances where GILD's MACD turned positive, the stock continued to rise in 35 of 54 cases over the following month. The odds of a continued upward trend are 65%.
Following a +7.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 216 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 129 of 264 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 49%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
GILD broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.893) is normal, around the industry mean (-1.376). GILD's P/E Ratio (-65.395) is considerably lower than the industry average of (21.842). Projected Growth (PEG Ratio) (2.263) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.039) among similar stocks. P/S Ratio (6.053) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic products and treatments for life threatening diseases
Industry PharmaceuticalsMajor
Advertisement